Company Overview
Snapshot
Founded in November 2010 by Yanay Ofran and Avi Molcho, Biolojic Design operates with 51–200 employees. The company has secured funding across three rounds from four investors. In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, potentially valued at up to 346 million euros.
Business overview
Biolojic Design is a biopharmaceutical company focused on developing human antibody-based therapeutics for cancer and other diseases. The company utilizes proprietary algorithms and computational tools to re-engineer antibodies, enabling them to bind new epitopes. This re-epitoping technology allows for the creation of functional antibodies for challenging targets. Biolojic Design operates within the Health Tech & Life Sciences sector, specifically in drug discovery and development, and serves the pharmaceutical and biotechnology industries.
Strategic signal
In June 2024, Biolojic Design announced a significant drug discovery collaboration with Merck, which could be worth up to 346 million euros. This partnership validates Biolojic Design's computational antibody design platform and its potential to accelerate the development of novel therapeutics, signaling strong commercial interest and potential for future growth in the biopharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent collaboration for Biolojic Design?
- In June 2024, Biolojic Design announced a drug discovery collaboration with Merck, which has a potential value of up to 346 million euros.
- Which company acquired rights to Biolojic Design's asthma treatment?
- In December 2023, Teva acquired the rights for Biolojic Design's asthma treatment.
- When did Biolojic Design appoint its Chief Scientific Officer?
- Biolojic Design appointed Ronald Herbst, Ph.D., as Chief Scientific Officer in September 2022.
- What was the nature of the collaboration between Biolojic Design and Lilly?
- In March 2021, Lilly and Biolojic Design announced a research collaboration to discover and develop antibody therapies for diabetes.